Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 116 articles: HTML format

Single Articles

April 2023
1. NASRAZADANI A, Li Y, Fang Y, Shah O, et al
   Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
   Br J Cancer. 2023;128:1030-1039.
   PubMed     Abstract available
   
   
   March 2023
2. BENIEY M, Hubert A, Haque T, Cotte AK, et al
   Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.
   Br J Cancer. 2023 Mar 20. doi: 10.1038/s41416-023-02226.
   PubMed     Abstract available
   
   
   
3. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
   Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
   Br J Cancer. 2023 Mar 13. doi: 10.1038/s41416-023-02206.
   PubMed    
   
   
   
4. GUO J, Hu J, Zheng Y, Zhao S, et al
   Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer.
   Br J Cancer. 2023 Mar 4. doi: 10.1038/s41416-023-02215.
   PubMed     Abstract available
   
   
   
5. CANAS-MARQUES R, Schnitt SJ
   Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?
   Br J Cancer. 2023;128:713-714.
   PubMed    
   
   
   
6. MAO N, Zhang H, Dai Y, Li Q, et al
   Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study.
   Br J Cancer. 2023;128:793-804.
   PubMed     Abstract available
   
   
   February 2023
7. HARVIE M, French DP, Pegington M, Lombardelli C, et al
   Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic.
   Br J Cancer. 2023 Feb 25:1-11. doi: 10.1038/s41416-023-02207.
   PubMed     Abstract available
   
   
   
8. ZHANG X, Jiang Q, Su Y, Bu L, et al
   AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
   Br J Cancer. 2023 Feb 17. doi: 10.1038/s41416-022-02127.
   PubMed     Abstract available
   
   
   
9. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
   Tumour-educated platelets for breast cancer detection: biological and technical insights.
   Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02174.
   PubMed     Abstract available
   
   
   
10. LUO J, Zou H, Guo Y, Tong T, et al
    The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02182.
    PubMed     Abstract available
    
    
    
11. USHER-SMITH JA, Hindmarch S, French DP, Tischkowitz M, et al
    Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.
    Br J Cancer. 2023 Feb 3:1-11. doi: 10.1038/s41416-023-02145.
    PubMed     Abstract available
    
    
    
12. CASTRO-ESPIN C, Bonet C, Crous-Bou M, Katzke V, et al
    Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study.
    Br J Cancer. 2023 Feb 3. doi: 10.1038/s41416-023-02169.
    PubMed     Abstract available
    
    
    
13. KUMEGAWA K, Saeki S, Takahashi Y, Yang L, et al
    Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
    Br J Cancer. 2023 Feb 1. doi: 10.1038/s41416-023-02178.
    PubMed     Abstract available
    
    
    
14. HOWELL A, Howell SJ
    Tamoxifen evolution.
    Br J Cancer. 2023;128:421-425.
    PubMed    
    
    
    
15. YUN J, Heo W, Lee ES, Na D, et al
    An integrative approach for exploring the nature of fibroepithelial neoplasms.
    Br J Cancer. 2023;128:626-637.
    PubMed     Abstract available
    
    
    January 2023
16. WU HL, Luo ZY, He ZL, Gong Y, et al
    Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02159.
    PubMed    
    
    
    
17. BOTTOSSO M, Griguolo G, Sinoquet L, Guarascio MC, et al
    Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02153.
    PubMed     Abstract available
    
    
    
18. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2023 Jan 25. doi: 10.1038/s41416-023-02161.
    PubMed    
    
    
    
19. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
    Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Br J Cancer. 2023 Jan 13. doi: 10.1038/s41416-022-02130.
    PubMed    
    
    
    December 2022
20. WU HL, Luo ZY, He ZL, Gong Y, et al
    All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111.
    PubMed     Abstract available
    
    
    
21. IBRAHIM SL, Abed MN, Mohamed G, Price JC, et al
    Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
    Br J Cancer. 2022 Dec 16. doi: 10.1038/s41416-022-02095.
    PubMed     Abstract available
    
    
    
22. ZHAO S, Pan T, Deng J, Cao L, et al
    Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02077.
    PubMed     Abstract available
    
    
    
23. YAZAKI S, Salgado R, Shimoi T, Yoshida M, et al
    Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.
    Br J Cancer. 2022 Dec 15. doi: 10.1038/s41416-022-02072.
    PubMed     Abstract available
    
    
    
24. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Dec 2. doi: 10.1038/s41416-022-02087.
    PubMed    
    
    
    
25. SHAABAN AM, Hilton B, Clements K, Dodwell D, et al
    The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion
    Br J Cancer. 2022;127:2125-2132.
    PubMed     Abstract available
    
    
    
26. SAHU R, Jha S, Pattanayak SP
    Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis.
    Br J Cancer. 2022;127:2207-2219.
    PubMed     Abstract available
    
    
    November 2022
27. DIECI MV, Carbognin L, Miglietta F, Canino F, et al
    Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02050.
    PubMed     Abstract available
    
    
    
28. GATHANI T, Dodwell D, Horgan K
    The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England.
    Br J Cancer. 2022 Nov 12. pii: 10.1038/s41416-022-02054.
    PubMed    
    
    
    
29. KOCK AM BRINK M, Dunst LS, Behrens HM, Kruger S, et al
    Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02047.
    PubMed     Abstract available
    
    
    
30. CURIGLIANO G, Shapiro GI, Kristeleit RS, Abdul Razak AR, et al
    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Br J Cancer. 2022 Nov 5. pii: 10.1038/s41416-022-02025.
    PubMed     Abstract available
    
    
    
31. SHI Q, Xuhong J, Luo T, Ge J, et al
    PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
    Br J Cancer. 2022 Nov 2. pii: 10.1038/s41416-022-02021.
    PubMed     Abstract available
    
    
    
32. DELACOTE C, Delacour-Billon S, Ayrault-Piault S, Tagri AD, et al
    Is survival rate lower after breast cancer in deprived women according to disease stage?
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02024.
    PubMed     Abstract available
    
    
    
33. SYRIOPOULOU E, Wasterlid T, Lambert PC, Andersson TM, et al
    Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data.
    Br J Cancer. 2022;127:1808-1815.
    PubMed     Abstract available
    
    
    
34. MORRISSEY RL, Thompson AM, Lozano G
    Is loss of p53 a driver of ductal carcinoma in situ progression?
    Br J Cancer. 2022;127:1744-1754.
    PubMed     Abstract available
    
    
    
35. LUNDBERG P, Forsgren MF, Tellman J, Kihlberg J, et al
    Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ.
    Br J Cancer. 2022;127:2025-2033.
    PubMed     Abstract available
    
    
    October 2022
36. HUDSON BI, Lippman ME
    Comment on "The lingering mysteries of metastatic recurrence in breast cancer".
    Br J Cancer. 2022 Oct 31. pii: 10.1038/s41416-022-02012.
    PubMed    
    
    
    
37. TRAN TV, Rubino C, Allodji R, Andruccioli M, et al
    Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
    Br J Cancer. 2022 Oct 12. pii: 10.1038/s41416-022-01982.
    PubMed     Abstract available
    
    
    
38. ZHANG M, Wang J, Jin Y, Zheng Q, et al
    YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation.
    Br J Cancer. 2022 Oct 10. pii: 10.1038/s41416-022-02006.
    PubMed     Abstract available
    
    
    
39. JACOT W, Lusque A, Vicier C, Mailliez A, et al
    Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
    Br J Cancer. 2022 Oct 7. pii: 10.1038/s41416-022-02003.
    PubMed     Abstract available
    
    
    
40. FALLOWFIELD L, Solis-Trapala I, Starkings R, May S, et al
    Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
    Br J Cancer. 2022;127:1116-1122.
    PubMed     Abstract available
    
    
    
41. STANNARD R, Lambert PC, Andersson TM, Rutherford MJ, et al
    Obtaining long-term stage-specific relative survival estimates in the presence of incomplete historical stage information.
    Br J Cancer. 2022;127:1061-1068.
    PubMed     Abstract available
    
    
    
42. SLOTH RA, Axelsen TV, Espejo MS, Toft NJ, et al
    Loss of RPTPgamma primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival.
    Br J Cancer. 2022;127:1226-1238.
    PubMed     Abstract available
    
    
    September 2022
43. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
    Br J Cancer. 2022 Sep 17. pii: 10.1038/s41416-022-01940.
    PubMed     Abstract available
    
    
    
44. FERNANDEZ-GARCIA D, Nteliopoulos G, Hastings RK, Rushton A, et al
    Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01962.
    PubMed     Abstract available
    
    
    
45. ZAGOURI F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, et al
    Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
    Br J Cancer. 2022;127:695-703.
    PubMed     Abstract available
    
    
    
46. LUO C, Zhao S, Peng C, Wang C, et al
    Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01958.
    PubMed     Abstract available
    
    
    
47. NADER-MARTA G, Debien V, Eiger D, Tsourti Z, et al
    Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01963.
    PubMed     Abstract available
    
    
    August 2022
48. WOOF VG, Howell A, McWilliams L, Gareth Evans D, et al
    How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research.
    Br J Cancer. 2022 Aug 24. pii: 10.1038/s41416-022-01944.
    PubMed     Abstract available
    
    
    
49. INGEBRIKTSEN LM, Finne K, Akslen LA, Wik E, et al
    A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01953.
    PubMed     Abstract available
    
    
    
50. DEBIK J, Schafer H, Andreassen T, Wang F, et al
    Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study.
    Br J Cancer. 2022 Aug 4. pii: 10.1038/s41416-022-01924.
    PubMed     Abstract available
    
    
    July 2022
51. SHU X, Zhou Q, Sun X, Flesaker M, et al
    Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis.
    Br J Cancer. 2022 Jul 26. pii: 10.1038/s41416-022-01923.
    PubMed     Abstract available
    
    
    
52. VAN DEN BOSCH T, Rueda OM, Caldas C, Vermeulen L, et al
    Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01906.
    PubMed     Abstract available
    
    
    
53. LI T, Houssami N, Noguchi N, Zeng A, et al
    Differential detection by breast density for digital breast tomosynthesis versus digital mammography population screening: a systematic review and meta-analysis.
    Br J Cancer. 2022;127:116-125.
    PubMed     Abstract available
    
    
    
54. ALLEN V, Coulombe J, Zhao H, Kreps LM, et al
    VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
    Br J Cancer. 2022;127:56-68.
    PubMed     Abstract available
    
    
    June 2022
55. ALMEKINDERS MM, Bismeijer T, Kumar T, Yang F, et al
    Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
    Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01888.
    PubMed     Abstract available
    
    
    
56. LOFLING LL, Stoer NC, Sloan EK, Chang A, et al
    beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01891.
    PubMed     Abstract available
    
    
    
57. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
    A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
    Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
    PubMed     Abstract available
    
    
    
58. BARTLOME S, Berry CC
    Recent insights into the effects of metabolism on breast cancer cell dormancy.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01869.
    PubMed     Abstract available
    
    
    
59. BAKER JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al
    Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01870.
    PubMed     Abstract available
    
    
    
60. SAURAV S, Manna SK
    Increased expression of Profilin potentiates chemotherapeutic agent-mediated tumour regression.
    Br J Cancer. 2022;126:1410-1420.
    PubMed     Abstract available
    
    
    May 2022
61. YAO X, He Z, Qin C, Zhang P, et al
    Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
    Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01834.
    PubMed     Abstract available
    
    
    
62. MICHMERHUIZEN AR, Lerner LM, Ward C, Pesch AM, et al
    Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01849.
    PubMed     Abstract available
    
    
    
63. VALACHIS A, Carlqvist P, Ma Y, Szilcz M, et al
    Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01845.
    PubMed     Abstract available
    
    
    
64. MIN HY, Lee HJ, Suh YA, Pei H, et al
    Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
    PubMed     Abstract available
    
    
    
65. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available
    
    
    April 2022
66. JAMES AD, Leslie TK, Kaggie JD, Wiggins L, et al
    Sodium accumulation in breast cancer predicts malignancy and treatment response.
    Br J Cancer. 2022 Apr 25. pii: 10.1038/s41416-022-01802.
    PubMed     Abstract available
    
    
    
67. UMEH-GARCIA M, O'Geen H, Simion C, Gephart MH, et al
    Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01812.
    PubMed     Abstract available
    
    
    
68. CHAUHAN A, Pal A
    Comments on "Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer".
    Br J Cancer. 2022 Apr 12. pii: 10.1038/s41416-022-01804.
    PubMed    
    
    
    March 2022
69. GAHLAWAT AW, Fahed L, Witte T, Schott S, et al
    Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer.
    Br J Cancer. 2022 Mar 22. pii: 10.1038/s41416-022-01756.
    PubMed     Abstract available
    
    
    
70. TOMICZEK-SZWIEC J, Szwiec M, Falco M, Cybulski C, et al
    The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01770.
    PubMed     Abstract available
    
    
    
71. CLIFT AK, Dodwell D, Lord S, Petrou S, et al
    The current status of risk-stratified breast screening.
    Br J Cancer. 2022;126:533-550.
    PubMed     Abstract available
    
    
    February 2022
72. DE GREGORIO A, Janni W, Friedl TWP, Nitz U, et al
    The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-021-01690.
    PubMed     Abstract available
    
    
    
73. MATIKAS A, Kotsakis A, Apostolaki S, Politaki H, et al
    Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
    Br J Cancer. 2022 Feb 10. pii: 10.1038/s41416-022-01699.
    PubMed     Abstract available
    
    
    
74. TUTZAUER J, Sjostrom M, Holmberg E, Karlsson P, et al
    Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-021-01630.
    PubMed     Abstract available
    
    
    
75. WEST CML
    Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01707.
    PubMed     Abstract available
    
    
    
76. DE BOO LW, Jozwiak K, Joensuu H, Lindman H, et al
    Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    Br J Cancer. 2022 Feb 5. pii: 10.1038/s41416-022-01711.
    PubMed     Abstract available
    
    
    
77. DUFFY SW, Seedat F, Kearins O, Press M, et al
    The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation.
    Br J Cancer. 2022 Feb 2. pii: 10.1038/s41416-022-01714.
    PubMed     Abstract available
    
    
    
78. BEDNARZ-KNOLL N, Popeda M, Kryczka T, Kozakiewicz B, et al
    Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas.
    Br J Cancer. 2022;126:464-471.
    PubMed     Abstract available
    
    
    January 2022
79. ZOU R, Loke SY, Tang YC, Too HP, et al
    Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01593.
    PubMed     Abstract available
    
    
    
80. NAGHAVI-BEHZAD M, Vogsen M, Vester RM, Olsen MMB, et al
    Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01654.
    PubMed     Abstract available
    
    
    December 2021
81. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available
    
    
    
82. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available
    
    
    
83. VEITCH Z, Ribnikar D, Tilley D, Tang PA, et al
    No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
    Br J Cancer. 2021 Dec 20. pii: 10.1038/s41416-021-01676.
    PubMed     Abstract available
    
    
    
84. HARVIE M, Pegington M, Howell SJ, Bundred N, et al
    Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01650.
    PubMed     Abstract available
    
    
    
85. HANNA K, Krzoska E, Shaaban AM, Muirhead D, et al
    Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01659.
    PubMed     Abstract available
    
    
    November 2021
86. CANELO-AYBAR C, Posso M, Montero N, Sola I, et al
    Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01521.
    PubMed     Abstract available
    
    
    
87. JAGGUPILLI A, Ly S, Nguyen K, Anand V, et al
    Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01636.
    PubMed     Abstract available
    
    
    
88. SCOTT NP, Teoh EJ, Flight H, Jones BE, et al
    Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
    Br J Cancer. 2021 Nov 18. pii: 10.1038/s41416-021-01623.
    PubMed     Abstract available
    
    
    
89. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available
    
    
    
90. SUPPAN C, Graf R, Jahn S, Zhou Q, et al
    Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
    Br J Cancer. 2021 Nov 9. pii: 10.1038/s41416-021-01601.
    PubMed     Abstract available
    
    
    
91. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    PubMed     Abstract available
    
    
    
92. PARKES EE, Savage KI, Lioe T, Boyd C, et al
    Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
    Br J Cancer. 2021 Nov 2. pii: 10.1038/s41416-021-01599.
    PubMed     Abstract available
    
    
    
93. VAN SEIJEN M, Lips EH, Fu L, Giardiello D, et al
    Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
    Br J Cancer. 2021;125:1443-1449.
    PubMed     Abstract available
    
    
    October 2021
94. HU J, Lai Y, Huang H, Ramakrishnan S, et al
    TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01596.
    PubMed     Abstract available
    
    
    
95. GUZMAN-AROCHO YD, Rosenberg SM, Garber JE, Vardeh H, et al
    Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01597.
    PubMed     Abstract available
    
    
    
96. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available
    
    
    
97. KNUTSEN E, Harris AL, Perander M
    Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01588.
    PubMed     Abstract available
    
    
    
98. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available
    
    
    
99. HERZOG SK, Fuqua SAW
    ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
    Br J Cancer. 2021 Oct 7. pii: 10.1038/s41416-021-01564.
    PubMed     Abstract available
    
    
    September 2021
100. BIZOT A, Karimi M, Rassy E, Heudel PE, et al
     Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
     Br J Cancer. 2021 Sep 29. pii: 10.1038/s41416-021-01555.
     PubMed     Abstract available
     
     
     
101. WANG C, Hu K, Luo C, Deng L, et al
     Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
     Br J Cancer. 2021 Sep 27. pii: 10.1038/s41416-021-01549.
     PubMed     Abstract available
     
     
     
102. GWILI N, Jones SJ, Amri WA, Carr IM, et al
     Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response.
     Br J Cancer. 2021;125:983-993.
     PubMed     Abstract available
     
     
     
103. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
     Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
     Br J Cancer. 2021;125:877-883.
     PubMed     Abstract available
     
     
     
104. BURNSIDE ES, Warren LM, Myles J, Wilkinson LS, et al
     Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case-control study.
     Br J Cancer. 2021;125:884-892.
     PubMed     Abstract available
     
     
     August 2021
105. AMIRI SOURI E, Chenoweth A, Cheung A, Karagiannis SN, et al
     Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer.
     Br J Cancer. 2021;125:748-758.
     PubMed     Abstract available
     
     
     July 2021
106. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
     CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
     Br J Cancer. 2021;125:176-189.
     PubMed     Abstract available
     
     
     June 2021
107. CHEN F, Han Y, Kang Y
     Bone marrow niches in the regulation of bone metastasis.
     Br J Cancer. 2021;124:1912-1920.
     PubMed     Abstract available
     
     
     May 2021
108. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
     Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
     Br J Cancer. 2021;124:1882-1890.
     PubMed     Abstract available
     
     
     
109. BARTSCH R, Singer CF, Pfeiler G, Hubalek M, et al
     Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
     Br J Cancer. 2021;124:1795-1802.
     PubMed     Abstract available
     
     
     March 2021
110. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
     The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
     PubMed     Abstract available
     
     
     
111. PAI BELLARE G, Saha B, Patro BS
     Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
     Br J Cancer. 2021;124:1260-1274.
     PubMed     Abstract available
     
     
     
112. BADVE SS, Cho S, Gokmen-Polar Y, Sui Y, et al
     Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
     Br J Cancer. 2021;124:1150-1159.
     PubMed     Abstract available
     
     
     
113. WINKLER C, Armenia J, Jones GN, Tobalina L, et al
     SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
     Br J Cancer. 2021;124:951-962.
     PubMed     Abstract available
     
     
     
114. ZENG Y, Gao W, Chen X, Shen K, et al
     Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
     Br J Cancer. 2021;124:975-981.
     PubMed     Abstract available
     
     
     
115. SHAABAN AM, Hilton B, Clements K, Provenzano E, et al
     Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
     Br J Cancer. 2021;124:1009-1017.
     PubMed     Abstract available
     
     
     February 2021
116. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
     Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
     Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: